Abstract: A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more known uricosurics are also set forth.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

Abstract: The invention involves methods for the treatment and prophylaxis of human or animal subjects having infectious gastrointestinal disorders of the upper gastrointestinal tract caused or mediated by Campylobacter-like organisms comprising the step of administering to the subjects safe and effective amounts of nitrofurantoin.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.

Abstract: The present invention provides indole derivatives of the general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl, alkenyl, cycloalkyl, cycloalkenyl, carboxyl, cyano, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or aryl radical, R.sub.2 is a hydrogen atom or an alkyl, trihalogenomethyl, hydroxyl, cycloalkyl, cyano, carboxyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl radical; R.sub.2 is a heterocyclic five-membered ring containing 1 to 4 heteroatoms or a heterocyclic six-membered ring containing 1 to 5 heteroatoms, the heteroatoms of the five- and six-membered rings being the same or different and being nitrogen, oxygen or sulphur and one or more of the nitrogen atoms optionally carrying an oxygen atom, the said five- and six-membered rings optionally being substituted by one or more alkyl, alkoxy, alkylthio, oxo, hydroxyl, nitro, amino, halogen or cyano groups; or R.sub.

Abstract: The invention involves a method for achieving systemic administration of azumolene by delivering the drug to the intestines without exposing the drug in the stomach, and pharmaceutical compositions for achieving such administration of azumolene.

Abstract: Novel substituted 4-[1H-imidazol-1-yl]benzamides and their use in the treatment of cardiac arrthythmias especially as Class III or combination Class I/III antiarrhythmic agents is described. Pharmaceutical formulations containing such compounds are also disclosed.

Abstract: A concentrated aqueous solution of the sodium salt of methionine, which is practically free from inorganic salts, is produced from the medium resulting from the hydrolysis of 5-(.beta.-mercaptoethyl)hydantoin.

Abstract: Disclosed herein are naphthalenylsulfonylimidazolidinediones and their thioxo analogs and methods for their preparation. The compounds are new aldose reductase inhibitors useful for the treatment or prevention of diabetic complications.

Abstract: 5-(2-methyl-2-thiol ethyl) hydantoin and derivatives thereof are useful in the treatment of evolutive chronic polyarthritis.

Abstract: Pharmaceutical compositions containing imidazolidinetrione derivatives or pharmaceutically acceptable salts thereof having hypoglycemic and hypolipidemic effects. The compositions comprise as an active ingredient at least one imidazolidinetrione derivative of the formula: ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, an alkyl group, a cycloalkyl group or ##STR2## and each of R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, halogen, a nitro group, a lower alkyl group or a lower alkoxy group.

Abstract: The present invention is directed to a novel process for manufacturing tablets of N-halohydantoin compounds. In the process, at least one dry, particulate N-halohydantoin compound is blended with a dry, particulate alkali metal or alkaline earth salt to form a dry mixture, and the mixture is compacted into densified forms such as tablets. Dry particulate alkali metal or alkaline earth salts consist of a cation selected from among the group comprising lithium, sodium, potassium, magnesium and calcium and an anion selected from among the group comprising carbonate, bicarbonate, borate, silicate, phosphate, percarbonate, and perphosphate, to form a dry mixture and compressing the mixture.The invention is further directed to tablets produced by this process. The invention is also directed to mixtures comprising N-halohydantoin, one-half to three percent by weight alkali metal or alkaline earth salt, minor components and less than about five percent water.

Abstract: Nontoxic, dry, powdered germicide, and healing compositions are disclosed comprising allantoin, ascorbic acid and an inert powdered carrier.

Abstract: Ureas of the formula (I): ##STR1## where R.sup.1 =alkoxy or alkylthio; R.sup.2 =alkyl; and Ar=substituted or unsubstituted phenyl, useful as anxiolytic agents as well as intermediates useful in the synthesis.

Abstract: This invention relates to a method for treating human beings and animals suffering from mental disorders comprising administering to said human beings and animals an effective amount of a compound for the treatment of such mental disorders comprising a compound having the formula ##STR1## wherein R is alkyl straight or branch chained having from 1 to 10 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, aralkyl having from 7 to 9 carbon atoms or phenyl unsubstituted or substituted by one to three F, Cl, Br, lower alkyl having from 1 to 5 carbon atoms, lower alkoxy having from 1 to 5 carbon atoms, alkylenedioxy having from 1 to 3 carbon atoms, --CF.sub.3 or --CN substituents, R.sub.1 -R.sub.4 are independently H, CH.sub.3, C.sub.2 H.sub.5 with cis or trans configuration provided that only two of them are other than hydrogen, and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to novel hydantoin derivatives represented by the general formula (I) and pharmaceutical compositions containing them as an active ingredient. ##STR1## In the formula (I), X is hydrogen or a group having the formula --OR.sub.4, and each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group.Hydantoin derivatives and pharmaceutically acceptable salts thereof of the present invention have excellent hypoglycemic, hypolipidemic and diuretic effects, as well as low toxicity and great safety. Therefore, the compounds of the present invention are not only useful as antidiabetics but also as drugs for hyperlipidemia.

Abstract: Described is a single phase clear hydroalcoholic after-shave treatment product containing aloe vera and, optionally, allantoin and a process for preparing same comprising the steps of:(a) either forming:(i) aloe vera gel; or(ii) a product resulting from steam distilling aloe vera leaves and separating the resulting oil phase from the resulting aqueous phase;(b) extracting the oil-miscible aloe vera fraction from the organic phase of the steam distillation product or from the aloe vera gel by intimately admixing therewith a quantity of extraction solvent and physically separating the extract phase from the raffinate phase;(c) separating the extraction solvent from the oil-miscible aloe vera extract phase by means of fractional distillation;(d) intimately admixing the resulting distilled oil-miscible aloe vera phase with a totally miscible perfume oil;(e) admixing the resulting mixture with a polyalkylene glycol, a polyalkylene glycol alkyl ether, a quaternary ammonium salt, a lanolin oil-polyalkylene glycol re

Abstract: Compounds of the formula: ##STR1## wherein R is aryl of 6 to 12 carbon atoms, substituted aryl substituted with 1 to 3 substituents independently selected from halogen lower alkyl of 1 to 4 carbon atoms, lower alkoxy of 1 to 4 carbon atoms, lower alkylthio of 1 to 4 carbon atoms, nitro, cyano or S(O).sub.n R.sup.4 wherein n is 1 or 2 and R.sup.4 is lower alkyl of 1 to 4 carbon atoms; lower alkylamino of 1 to 6 carbon atoms; the group ##STR2## where R.sup.5 and R.sup.6 are independently hydrogen, lower alkyl of 1 to 6 carbon atoms, aryl or substituted aryl; or alkyl of 1 to 10 carbon atoms, lower cycloalkyl of 3 to 8 carbon atoms, lower alkenyl of 2 to 6 carbon atoms, lower alkynyl of 2 to 6 carbon atoms, alkoxyalkyl of 2 to 8 carbon atoms, or alkylthioalkyl of 2 to 8 carbon atoms, all optionally substituted with 1 to 3 halogen atoms; R.sup.1 and R.sup.2 are independently hydrogen, or lower alkyl of 1 to 6 carbon atoms; and R.sup.

Abstract: A composition of matter comprising a major part of imidazolidinyl urea and a minor part of pyrithione and/or one or more derivatives of pyrithione is disclosed. The composition exhibits synergistic anti-microbial activity.

Abstract: Spiro-oxazolidones, -thiazolidones and -imidazolidones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic complications are also disclosed.

Abstract: The new hydantoins of the formula ##STR1## in which R.sup.1 denotes an optionally substituted alkyl, alkenyl, cycloalkyl or aralkyl radical andR.sup.2 and R.sup.3 are identical or different and denote hydrogen, alkyl or alkenyl or are linked to form a cycloalkyl radical,can be prepared by reacting a corresponding hydantoin with dichlorofluoromethanesulphenyl chloride. The new compounds can be used as active compounds in microbicidal agents.

Abstract: Dantrolene sodium is useful as a cardiac antiarrhythmic agent in hypothermic and normothermic warm-blooded animals.

Abstract: N-Sulphenylated hydantoins of the formula ##STR1## in which R.sup.1 is trihalogenomethoxy or trihalogenomethylmercapto,R.sup.2 is hydrogen, nitro or halogen, andR.sup.3 and R.sup.4 each independently is hydrogen or alkyl, or, together with the ring carbon atom at which they are located, form a five-membered or six-membered cycloalkyl radical,which possess fungicidal activity.